Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can Urine-Guided diuretic doses improve heart failure treatment?

NCT ID NCT07804654

Disease control Sponsor: Universiti Teknologi Mara Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 04, 2026 · Last updated Sep 04, 2026

Summary

This trial tests whether giving higher or lower doses of a water-removing medicine, guided by urine sodium and output, helps adults hospitalized with acute heart failure. Researchers compare two urine-guided strategies with standard care, measuring how much sodium and urine the body removes in the first 24 hours, along with symptom relief and safety. The goal is to find a more effective way to reduce fluid buildup and improve short-term outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Intravenous furosemide (a water-removing medicine) given in high or low doses, guided by urine sodium and output, compared with standard care.
What this could lead to
If it works, this could point toward a more effective way to use diuretics in acute heart failure, potentially easing symptoms and shortening hospital stays.
What could go wrong
This is a small pilot study, so results may not apply broadly. Higher diuretic doses can affect kidney function, and the approach may not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

109 people

The number who actually took part.

Started

Jan 2026

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older * Malaysian nationality * Hospitalised with acute heart failure, either de novo acute heart failure or acute decompensated chronic heart failure * Clinical evidence of congestion requiring intravenous loop diuretic therapy, with at least one of the following: peripheral oedema, orthopnoea, paroxysmal nocturnal dyspnoea, pulmonary crepitations, elevated jugular venous pressure, ascites, or congestive hepatomegaly * Able to provide informed consent Exclusion Criteria: * End-stage renal disease requiring chronic dialysis * Requirement or anticipated requirement for invasive mechanical ventilation * Requirement or anticipated requirement for inotropic or vasopressor support * Requirement or anticipated requirement for renal replacement therapy * Cardiogenic shock or systolic blood pressure below 100 mmHg * Pregnancy or breastfeeding * Known hypersensitivity to furosemide

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute heart failure (AHF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute heart failure (AHF)

Contacts and locations

Locations

  • Hospital Al-Sultan Abdullah, Universiti Teknologi MARA

    Shah Alam, Selangor, 42300, Malaysia

More trials for these conditions

Other studies related to the condition(s) this trial covers.